Furthermore, CSF2-cFLiMo can overcome the limitation in macrophage precursor numbers and be used as a therapeutic approach for PAP disease or in other macrophage-based cell therapies, including lung emphysema, lung fibrosis, lung infectious disease, and lung cancer (33–35). This evidence concerns the gene CSF2 and lung cancer.